<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203311433139</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203311433139</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Lupus around the world</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Analysis of 15 patients with systemic lupus erythematosus manifesting with negative immunofluorescence anti-nuclear antibodies after treatment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Song</surname><given-names>L-J</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Ding</surname><given-names>F</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>H-X</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Shu</surname><given-names>Q</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Yu</surname><given-names>X</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>J</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Li</surname><given-names>X-F</given-names></name>
<xref ref-type="corresp" rid="corresp1-0961203311433139"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203311433139">Department of Rheumatology, Qilu Hospital of Shandong University, Jinan, P.R. China</aff>
<author-notes>
<corresp id="corresp1-0961203311433139">Xing-Fu Li, Department of Rheumatology, Qilu Hospital of Shandong University, 107# Wenhuaxi Road, Jinan 250012, China Email: <email>drxfuli@126.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>8</issue>
<fpage>919</fpage>
<lpage>924</lpage>
<history>
<date date-type="received"><day>7</day><month>9</month><year>2011</year></date>
<date date-type="accepted"><day>10</day><month>11</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2011. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The purpose of this study was to investigate the clinical and laboratorial characteristics of patients with systemic lupus erythematosus (SLE) manifesting with negative immunofluorescence anti-nuclear antibodies (IFANA) after treatment for the better understanding of negative conversion of IFANA. Demographic characteristics, clinical and laboratory data of hospitalized SLE patients between March 2006 and May 2011 were retrospectively reviewed. Fifteen cases with negative IFANA were identified in 960 patients. All of the 15 patients were severe, 11 patients manifested with nephritic range proteinuria and hypoalbuminemia, 8 patients were complicated with severe infection and all of the patients had been treated with glucocorticoid and immunosuppressant. Anti-ENA antibodies were positive in 4 of 15 patients. Eight patients died after average 1-year follow-up. Collectively, negative IFANA is mainly attributed to nephritic-range proteinuria; and large-dose glucocorticoid, immunosuppressant and severe infection are also important factors for negative IFANA. Antinuclear antibody can be detected in some SLE patients with negative IFANA by changing the detection method and titer. Negative conversion of IFANA often indicates unfavorable prognosis for severe patients.</p>
</abstract>
<kwd-group>
<kwd>glucocorticoid</kwd>
<kwd>immunofluorescence anti-nuclear antibodies</kwd>
<kwd>infection</kwd>
<kwd>lupus nephritis</kwd>
<kwd>systemic lupus erythematosus</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203311433139" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is the prototypic autoimmune disorder characterized by the production of multiple autoantibodies to components of the cell nucleus and the involvement of multiple systems. Indirect immunofluorescence anti-nuclear antibody (IFANA) is one of the fundamental methods for screening of SLE. SLE almost can be excluded if the anti-nuclear antibody (ANA) test comes back negative and usually no further testing is needed. A few IFANA-positive SLE patients present with negative IFANA after treatment. People have always been arguing whether ANA-negative lupus really exists; meanwhile, whether IFANA shifting from positive to negative means patients getting better or worse is still unknown. This study analyses the characteristics of 15 patients with SLE manifesting with negative IFANA and discusses the possible reasons and clinical value of negative conversion of IFANA.</p></sec>
<sec id="sec2-0961203311433139" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-0961203311433139" sec-type="subjects"><title>Patients</title>
<p>A retrospective medical records review was performed in hospitalized patients with SLE who were admitted to Qilu Hospital of Shandong University between March 2006 and July 2011. All of the patients fulfilled the American College of Rheumatology revised criteria for the classification of SLE in 1997.<sup><xref ref-type="bibr" rid="bibr1-0961203311433139">1</xref></sup> All of the SLE patients with negative IFANA after treatment were enrolled in this study, and all of the patients were IFANA positive as some point, and all of the patients had a history of glucocorticoid and immunosuppressant therapy.</p>
<p>The following clinical and laboratory data were recorded: age, gender, clinical symptoms and signs; routine test such as complete blood count, routine urinalysis, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP); immunologic tests such as IFANA, anti-ENA (Extractable Nuclear Antigens) antibody including anti-Sm, anti-U<sub>1</sub>RNP, anti-SSA, anti-SSB, anti-Jo-1 and anti-Scl-70 antibodies, anti-dsDNA antibody, serum complement and immunoglobulin levels; SLE Disease Activity Index (SLEDAI);<sup><xref ref-type="bibr" rid="bibr2-0961203311433139">2</xref></sup> history of steroid therapy and the use of other immunosuppressive agents. ANA was tested by using EUROLIN indirect immunofluorescence (IIF), the initial dilutability was 1:100 according to the instruction of EUROLIN kit, and a titer of 1:100 or greater was considered positive.</p></sec>
<sec id="sec4-0961203311433139"><title>Statistical analysis</title>
<p>Data were processed by SPSS 13.0 for Windows and presented as mean ± SD.</p></sec></sec>
<sec id="sec5-0961203311433139" sec-type="results"><title>Results</title>
<sec id="sec6-0961203311433139"><title>Clinical characteristics</title>
<p>During the study period, 960 patients with SLE had been admitted to our hospital, of whom 15 SLE patients were identified as negative IFANA. There were 11 females and 4 males, aged between 13 and 67 (39.2 ± 14.8). The disease duration from the onset of SLE to the presence of negative IFANA varied from 13 to 120 months (54.3 ± 29.2). The SLEDAI scores ranged from 2 to 31 (18.5 ± 7.8). The clinical and demographic features of IFANA-negative SLE patients are shown in <xref ref-type="table" rid="table1-0961203311433139">Table 1</xref>. Except for mild manifestation of diseases such as alopecia, oral ulcer, photosensitivity, arthritis and Raynaud phenomenon, almost all of the patients presented with severe multisystemic involvement, especially lupus nephritis and secondary nephritic syndrome. All of the patients were diagnosed with severe lupus, the disease activity index was high in 13 of 15 patients with the SLEDAI≥15, and normal in the other 2 patients presenting with resistant severe thrombocytopenia.
<table-wrap id="table1-0961203311433139" position="float"><label>Table 1</label><caption><p>Clinical and demographic features and prognosis of 15 systemic lupus erythematosus patients with negative immunofluorescence anti-nuclear antibodies (IFANA)</p></caption>
<graphic alternate-form-of="table1-0961203311433139" xlink:href="10.1177_0961203311433139-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Patient number</th>
<th>Sex</th>
<th>Disease duration (months)</th>
<th>Main clinical manifestation</th>
<th>SLEDAI (scores)</th>
<th>Infection</th>
<th>Prognosis</th></tr></thead>
<tbody align="left">
<tr>
<td>1</td>
<td>Male</td>
<td>33</td>
<td>Alopecia, oral ulcer, arthritis, Raynaud phenomenon, pleural effusion, nephritic syndrome and renal insufficiency</td>
<td>22</td>
<td>Yes</td>
<td>Death</td></tr>
<tr>
<td>2</td>
<td>Female</td>
<td>45</td>
<td>Fever, gastrointestinal hemorrhage and ecchymosis</td>
<td>2</td>
<td>No</td>
<td>Survival</td></tr>
<tr>
<td>3</td>
<td>Male</td>
<td>28</td>
<td>Alopecia, oral ulcer, arthritis, Raynaud phenomenon, pleural effusion, nephritic syndrome, renal insufficiency and NPSLE</td>
<td>26</td>
<td>Yes</td>
<td>Death</td></tr>
<tr>
<td>4</td>
<td>Female</td>
<td>38</td>
<td>Ecchymosis, malar rash and pulmonary hypertension</td>
<td>3</td>
<td>No</td>
<td>Survival</td></tr>
<tr>
<td>5</td>
<td>Female</td>
<td>48</td>
<td>Alopecia, oral ulcer, Raynaud phenomenon, pulmonary hypertension, nephritic syndrome</td>
<td>16</td>
<td>No</td>
<td>Survival</td></tr>
<tr>
<td>6</td>
<td>Female</td>
<td>66</td>
<td>Alopecia, oral ulcer, pleural effusion, pulmonary hypertension, nephritic syndrome and renal insufficiency</td>
<td>18</td>
<td>Yes</td>
<td>Death</td></tr>
<tr>
<td>7</td>
<td>Female</td>
<td>36</td>
<td>Alopecia, rash, arthritis, pulmonary hypertension and nephritic syndrome</td>
<td>20</td>
<td>Yes</td>
<td>Survival</td></tr>
<tr>
<td>8</td>
<td>Female</td>
<td>68</td>
<td>Fever, rash, Raynaud phenomenon, arthritis, nephritic syndrome and renal insufficiency</td>
<td>15</td>
<td>No</td>
<td>Survival</td></tr>
<tr>
<td>9</td>
<td>Female</td>
<td>120</td>
<td>Fever, malar rash, oral ulceration, arthritis, nephritic syndrome, renal insufficiency and NPSLE</td>
<td>28</td>
<td>Yes</td>
<td>Death</td></tr>
<tr>
<td>10</td>
<td>Female</td>
<td>50</td>
<td>Fever, oral ulceration, alopecia, ecchymosis, pulmonary hypertension, nephritic syndrome and renal insufficiency</td>
<td>19</td>
<td>Yes</td>
<td>Death</td></tr>
<tr>
<td>11</td>
<td>Female</td>
<td>84</td>
<td>Alopecia, rash, oral ulceration, pulmonary hypertension and nephritic syndrome</td>
<td>20</td>
<td>Yes</td>
<td>Death</td></tr>
<tr>
<td>12</td>
<td>Male</td>
<td>13</td>
<td>Alopecia, rash, oral ulceration, pleuritis and nephritic syndrome</td>
<td>20</td>
<td>No</td>
<td>Survival</td></tr>
<tr>
<td>13</td>
<td>Male</td>
<td>24</td>
<td>Alopecia, rash, oral ulceration, pleuritis, purpura and NPSLE</td>
<td>31</td>
<td>No</td>
<td>Death</td></tr>
<tr>
<td>14</td>
<td>Female</td>
<td>96</td>
<td>Fever, malar rash, oral ulceration, arthritis, nephritic syndrome</td>
<td>20</td>
<td>Yes</td>
<td>Death</td></tr>
<tr>
<td>15</td>
<td>Female</td>
<td>66</td>
<td>Alopecia, oral ulcer, pleural effusion, pulmonary hypertension, proteinuria</td>
<td>18</td>
<td>No</td>
<td>Survival</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203311433139"><p>SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; NPSLE, neuropsychiatric systemic lupus erythematosus.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The patients manifested with significant abnormality in laboratory tests. The ESR ranged from 15 to 112 mm/h (58.0 ± 26.8), and only one patient had normal ESR. The CRP varied from 4 to 128 mg/l (51.8 ± 37.7) with three patients being normal. Among the 15 patients, 11 manifested with nephrotic-range proteinuria and hypoalbuminemia, 7 of these 11 presented with hypoglobulinemia in the serum at the same time, and 6 with renal insufficiency. Thirteen patients presented with hypocomplementemia, among whom 12 showed a decrease of both C3 and C4, one only C3. Two patients showed positive anti-SSA antibody and anti-SSB antibody, and two only positive anti-SSA antibody (<xref ref-type="table" rid="table2-0961203311433139">Table 2</xref>).
<table-wrap id="table2-0961203311433139" position="float"><label>Table 2</label><caption><p>Biochemical and immunological features of 15 SLE patients with negative immunofluorescence anti-nuclear antibodies (IFANA)</p></caption>
<graphic alternate-form-of="table2-0961203311433139" xlink:href="10.1177_0961203311433139-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Patient number</th>
<th>Nephrotic-range proteinuria</th>
<th>Hypoalbuminemia</th>
<th>Hypoglobulinemia</th>
<th>ESR(mm/h)</th>
<th>CRP(mg/l)</th>
<th>Complement (C3,C4)</th>
<th>Anti-ENA antibody</th></tr></thead>
<tbody align="left">
<tr>
<td>1</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>68</td>
<td>63</td>
<td>C3↓,C4↓</td>
<td>Negative</td></tr>
<tr>
<td rowspan="2">2</td>
<td rowspan="2">No</td>
<td rowspan="2">No</td>
<td rowspan="2">No</td>
<td rowspan="2">15</td>
<td rowspan="2">4</td>
<td rowspan="2">Normal</td>
<td>Anti-SSA antibody(+)</td></tr>
<tr>
<td>Anti-SSB antibody(+)</td></tr>
<tr>
<td>3</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>38</td>
<td>38</td>
<td>C3↓,C4↓</td>
<td>Negative</td></tr>
<tr>
<td>4</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>23</td>
<td>7</td>
<td>C3↓</td>
<td>Negative</td></tr>
<tr>
<td>5</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>66</td>
<td>68</td>
<td>C3↓,C4↓</td>
<td>Negative</td></tr>
<tr>
<td>6</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>45</td>
<td>80</td>
<td>C3↓,C4↓</td>
<td>Anti-SSA antibody(+)</td></tr>
<tr>
<td>7</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>90</td>
<td>75</td>
<td>C3↓,C4↓</td>
<td>Negative</td></tr>
<tr>
<td>8</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>85</td>
<td>128</td>
<td>C3↓,C4↓</td>
<td>Negative</td></tr>
<tr>
<td rowspan="2">9</td>
<td rowspan="2">Yes</td>
<td rowspan="2">Yes</td>
<td rowspan="2">No</td>
<td rowspan="2">112</td>
<td rowspan="2">114</td>
<td rowspan="2">Normal</td>
<td>Anti-SSA antibody(+)</td></tr>
<tr>
<td>Anti-SSB antibody(+)</td></tr>
<tr>
<td>10</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>60</td>
<td>36</td>
<td>C3↓,C4↓</td>
<td>Negative</td></tr>
<tr>
<td>11</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>76</td>
<td>44</td>
<td>C3↓,C4↓</td>
<td>Anti-SSA antibody(+)</td></tr>
<tr>
<td>12</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>66</td>
<td>34</td>
<td>C3↓,C4↓</td>
<td>Negative</td></tr>
<tr>
<td>13</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>34</td>
<td>18</td>
<td>C3↓,C4↓</td>
<td>Negative</td></tr>
<tr>
<td>14</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>58</td>
<td>62</td>
<td>C3↓,C4↓</td>
<td>Negative</td></tr>
<tr>
<td>15</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>34</td>
<td>6</td>
<td>C3↓,C4↓</td>
<td>Negative</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203311433139"><p>ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>All of the 15 patients had been treated with glucocorticoid before the IFANA was identified as negative, 10 of whom had received pulse intravenous methylprednisolone therapy, 0.5–1 g for 3 days. All 15 patients had previously received concomitant immunosuppressive agents such ascyclophosphamide, mycophenolate mofetil, <italic>Tripterygium wilfordii</italic> and cyclosporine. During their hospitalization, seven patients continued the treatment with immunosuppressive agents, while the other eight stopped the use of immunosuppressive agents because of severe infection. <xref ref-type="table" rid="table3-0961203311433139">Table 3</xref> shows the postulated reasons of IFANA becoming negative in 15 SLE patients. Over a mean follow-up of 1 year, eight patients died (53.3%), five of whom died from severe infection, one chronic renal insufficiency and tow neuropsychiatric SLE (NPSLE).
<table-wrap id="table3-0961203311433139" position="float"><label>Table 3</label><caption><p>Postulating reasons of immunofluorescence anti-nuclear antibodies (IFANA) becoming negative in every systemic lupus erythematosus patient</p></caption>
<graphic alternate-form-of="table3-0961203311433139" xlink:href="10.1177_0961203311433139-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Patient number</th>
<th>Postulating reasons</th></tr></thead>
<tbody align="left">
<tr>
<td>1</td>
<td>Nephritic-range proteinuria, glucocorticoid and immunosuppressant, infection</td></tr>
<tr>
<td>2</td>
<td>Glucocorticoid and immunosuppressant, test method</td></tr>
<tr>
<td>3</td>
<td>Nephritic-range proteinuria, glucocorticoid and immunosuppressant, infection</td></tr>
<tr>
<td>4</td>
<td>Glucocorticoid and immunosuppressant</td></tr>
<tr>
<td>5</td>
<td>Nephritic-range proteinuria, glucocorticoid and immunosuppressant,</td></tr>
<tr>
<td>6</td>
<td>Nephritic-range proteinuria, glucocorticoid and immunosuppressant, infection, test method</td></tr>
<tr>
<td>7</td>
<td>Nephritic-range proteinuria, glucocorticoid and immunosuppressant, infection</td></tr>
<tr>
<td>8</td>
<td>Nephritic-range proteinuria, glucocorticoid and immunosuppressant,</td></tr>
<tr>
<td>9</td>
<td>Nephritic-range proteinuria, glucocorticoid and immunosuppressant, infection, test method</td></tr>
<tr>
<td>10</td>
<td>Nephritic-range proteinuria, glucocorticoid and immunosuppressant, infection</td></tr>
<tr>
<td>11</td>
<td>Nephritic-range proteinuria, glucocorticoid and immunosuppressant, infection, test method</td></tr>
<tr>
<td>12</td>
<td>Nephritic-range proteinuria, glucocorticoid and immunosuppressant,</td></tr>
<tr>
<td>13</td>
<td>Glucocorticoid and immunosuppressant,</td></tr>
<tr>
<td>14</td>
<td>Nephritic-range proteinuria, infection</td></tr>
<tr>
<td>15</td>
<td>Glucocorticoid and immunosuppressant,</td></tr>
</tbody>
</table>
</table-wrap></p></sec></sec>
<sec id="sec7-0961203311433139" sec-type="discussion"><title>Discussion</title>
<p>In general, detectable positive IFANA means thepossibility of SLE and further tests such as antibodies to Sm, Ro/SSA, La/SSB, RNP and double-stranded DNA need to be performed. The possibility of SLE is very small if IFANA is negative. About 5% of SLE patients who fulfill the American College of Rheumatology (ACR) revised criteria for the classification of SLE in 1997 are ANA negative.<sup><xref ref-type="bibr" rid="bibr1-0961203311433139">1</xref></sup> Because the ACR classification criteria for SLE in 1997 were not validated, the SLICC group undertook a revision in 2009.<sup><xref ref-type="bibr" rid="bibr3-0961203311433139">3</xref></sup> Thenew revision emphasized the importance of immunologic abnormality; however, positive ANA was not necessary for the diagnosis of SLE. There is no consensus on the exact reasons for negative ANA and the clinical significance of ANA shifting from positive to negative.<sup><xref ref-type="bibr" rid="bibr4-0961203311433139">4</xref></sup></p>
<p>The disease stage of SLE can be evaluated by confrontation between ANA and other activity parameters.<sup><xref ref-type="bibr" rid="bibr5-0961203311433139">5</xref></sup> In our present study, we evaluated the disease activity of SLE patients using SLEDAI model. Although there are many other predictive models for SLE disease severity such as SLAM (Systemic Lupus Activity Measure), OUT (Henk Jan Out score), SIS (SLE Index Score) and BILAG (British Isles Lupus Assessment Group), SLEDAI is still the most widely accepted clinical model for SLE disease activity in most countries.<sup><xref ref-type="bibr" rid="bibr6-0961203311433139">6</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr11-0961203311433139">11</xref></sup> In our present study, the elevated SLEDAI scores were found in 13 of 15 patients, which indicated that most of the patients were at an active and inflammatory stage. These results also showed that ANA titer was not usually in accordance with SLE disease activity in certain SLE populations.</p>
<p>The plasma cells usually show high activity in producing autoantibody including ANA when SLE becomes active. Negative ANA often indicates that the antibody level is low and cannot be detected in the blood of SLE patients. Multiple factors can affect the result of autoantibody test and make ANA test negative: decrease of autoantibody production because of immune system being inactive or inhibited, excessive consumption of autoantibody because of the formation of immune complex and significant loss of immunoglobulin including autoantibody. <xref ref-type="table" rid="table3-0961203311433139">Table 3</xref> postulates the reasons for negativity of IFANA and <xref ref-type="table" rid="table4-0961203311433139">Table 4</xref> summarizes different categories of patients with negative IFANA and possible explanations for each category.
<table-wrap id="table4-0961203311433139" position="float"><label>Table 4</label><caption><p>Types of patients in whom immunofluorescence anti-nuclear antibodies (IFANA) becomes negative and postulating reasons for every type</p></caption>
<graphic alternate-form-of="table4-0961203311433139" xlink:href="10.1177_0961203311433139-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Patient types</th>
<th colspan="2">Postulating reasons</th></tr></thead>
<tbody align="left">
<tr>
<td rowspan="5">Severe patient</td>
<td rowspan="2">Decrease of autoantibody production</td>
<td>Glucocorticoid and immunosuppressant</td></tr>
<tr>
<td>Infection</td></tr>
<tr>
<td>Excessive consumption of autoantibody</td>
<td>Immune complex</td></tr>
<tr>
<td>Loss of immunoglobulin</td>
<td>Nephritic-range proteinuria</td></tr>
<tr>
<td>Test method</td>
<td>Distribution of autoantigen</td></tr>
<tr>
<td rowspan="2">Mild patient</td>
<td colspan="2">Long-term stable condition of disease activity</td></tr>
<tr>
<td colspan="2">Long-term maintenance therapy of low-dose glucocorticoid</td></tr>
</tbody>
</table>
</table-wrap></p>
<p>Renal involvement is a major cause of morbidity and hospital admissions in SLE patients and occurs in 40–70% of all patients. Almost half of patients present with asymptomatic urine abnormalities, such as hematuria and proteinuria. Nephrotic or nephritic syndrome or both also may be observed in 30% of patients. In this study, 11 patients presented with nephritic syndrome, 7 of whom were accompanied with hypoglobulinemia and 6 with renal insufficiency. Mild lupus nephritis mainly manifests with urine microalbumin and a few to medium proteinuria, small quantities of albumin and equivalent amounts of other proteins are predominant components. However, severe lupus nephritis frequently manifests with nephritic-range proteinuria, which means the large discharge of notonly the albumin but also the globulin including ANA and complement,<sup><xref ref-type="bibr" rid="bibr12-0961203311433139">12</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr14-0961203311433139">14</xref></sup> resulting in the decrease of globulin and complement in serum, therefore, the patients present with negative IFANA in the blood. In this condition, serum IFANA titer cannot reflect the disease activity, but is determined by the difference between ANA production from plasma cell and ANA discharge from urine.</p>
<p>It is reported that high-dose glucocorticoid could affect the titer of ANA.<sup><xref ref-type="bibr" rid="bibr15-0961203311433139">15</xref></sup> The long-term usage of large-dose glucocorticoid and immunosuppressant can inhibit the function of immune system and decrease the production of autoantibody, which lead to the negative result of ANA detection due to the decreased titer of antibody. The disease activity was severe in 13 patients with SLEDAI ≥15 and all 13 of these patients had a history of long-term usage of glucocorticoid and immunosuppressant. The other two patients were treated with long-term glucocorticoid because of refractory severe thrombocytopenia although their SLEDAI scores were normal. Therefore, negative IFANA in SLE patients was partially attributed to the long-term and large usage of glucocorticoid and immunosuppressant.</p>
<p>Eight patients complicated with severe infection in this study. Infection, especially invasive fungal infection, usually indicated that the immune function of the whole body was in an extremely weak condition. It had been reported that the patients with severe infection, especially with sepsis presented with a caspase-9-mediated profound progressive loss of B and CD4 + T helper cells, and the frequency of HLA-DR-antigen expression on monocytes and immunoglobulin including IgA, IgM and IgG were abnormally reduced in patients with sepsis, all of which contributed to the result ofnegative IFANA. Decreased immunoglobulin insevere infection patients was a potential factor for bad prognosis.<sup><xref ref-type="bibr" rid="bibr16-0961203311433139">16</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr18-0961203311433139">18</xref></sup> In our present study, in the patients with severe infection, 5 presented with hypoglobulinemia, and the mortality rate reached up to 87.5% (7/8) in these infected patients, which was in accordance with above reports.</p>
<p>A few mild SLE patients similarly presented withnegative IFANA, which was attributed to the long-term stable condition of disease activity and the long-term maintenance therapy of low-dose glucocorticoid (<xref ref-type="table" rid="table3-0961203311433139">Table 3</xref>). The abnormal immune response was in an idle state and the titer of ANA was in a relatively low level in these patients, which similarly contributed to negative IFANA. Thedecline of ANA together with the other autoantibodies is an indication of remission for these patients.</p>
<p>What should be emphasized is that most of the SLE patients with negative IFANA were not truly ANA-negative due to the various test methods and initial dilution. ANA could be detected by lowering serum dilution or using other methods such as ELISA and Western blot. The sera of all 15 patients were detected for anti-ENA antibody by Euroassay and Euroline. The results displayed that two patients had both positive anti-SSA antibody and positive anti-SSB antibody, and two patients only had positive anti-SSA antibody. Reichlin first reported the anti-RNP antibody and detected all of the sera from patients with negative ANA test on mouse liver in 2000 by ELISA, the methodology showed that 100% of the sera had elevated levels of anti-Ro/SSA, 46% had elevated levels of anti-La/SSB, and 35% had elevated levels of anti-U<sub>1</sub>RNP.<sup><xref ref-type="bibr" rid="bibr19-0961203311433139">19</xref></sup> SSA and SSB antigens were mainly located in cytoplasm and were relatively less in mouse liver cytoplasm than in human Hep-2 cells, which contributed to the low detection rate of ANA.<sup><xref ref-type="bibr" rid="bibr20-0961203311433139">20</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr22-0961203311433139">22</xref></sup> Wallace and Linker-Israeli considered that ANA-negative lupus would no longer exist when human substrates (Hep-2) replaced animal tissues for detection of IFANA.<sup><xref ref-type="bibr" rid="bibr23-0961203311433139">23</xref></sup></p>
<p>In theory, any antibody necessarily originates and perishes. As we have known, some antibodies can exist in the whole duration of disease even if the disease has healed, and the other antibodies fade away with the extension of time and therapy, both of which are partially associated with the half-life of antibodies. Antibody usually fades away without antigen but can be sustained by the long-lived plasmacytes. These cells can exist for the lifetime<sup><xref ref-type="bibr" rid="bibr24-0961203311433139">24</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr27-0961203311433139">27</xref></sup> because they can migrate to survival niches within the bone marrow,<sup><xref ref-type="bibr" rid="bibr24-0961203311433139">24</xref>,<xref ref-type="bibr" rid="bibr28-0961203311433139">28</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr31-0961203311433139">31</xref></sup> and not be depleted by glucocorticoid and immunosuppressant as well as monoclonal antibodies targeting to CD20<sup>+</sup>B cells.<sup><xref ref-type="bibr" rid="bibr32-0961203311433139">32</xref>,<xref ref-type="bibr" rid="bibr33-0961203311433139">33</xref></sup> This phenomenon means that antibodies such as ANA rarely thoroughly disappear even though there is no antigen stimulation in SLE patients. Therefore, the undetectable IFANA in our present study might be attributed to the low titer of Abs in the sera but not the regression of antigen stimulation.</p>
<p>The predominant mortality of SLE patients was attributed to infection, neuropsychiatric SLE and chronic renal insufficiency.<sup><xref ref-type="bibr" rid="bibr34-0961203311433139">34</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr36-0961203311433139">36</xref></sup> In this study, five patients died from severe infection, one from chronic renal insufficiency and two from NPSLE. More than half of the patients died over a mean follow-up of 1 year with 46.7% survival rate, which was far below the average 90% 5-year survival rate. Therefore, negative conversion of IFANA maybe indicates a poor prognosis for severe SLE, which needs our close attention.</p>
<p>In short, ANA is the core of development and diagnosis of SLE. Current evidence suggests that SLE is an ANA disorder and true ANA-negative lupus is an extremely rare event. Persistent and severe proteinuria contributes to the predominant part of negative ANA results; glucocorticoid, immunosuppressant and severe infection are also important impact factors for negative ANA. ANA can be detected in most SLE patients with negative ANA by altering the test method and titer. Negative conversion of IFANA may indicate poor prognoses for severe lupus patients.</p></sec>
</body>
<back>
<sec id="sec8-0961203311433139"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></sec>
<sec id="sec9-0961203311433139"><title>Conflict of interest statement</title>
<p>The authors declare no conflicts of interest in preparing this article.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203311433139"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr2-0961203311433139"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Ibanez</surname><given-names>D</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name></person-group>. <article-title>Systemic lupus erythematosus disease activity index 2000</article-title>. <source>J Rheumatol</source> <year>2002</year>; <volume>29</volume>: <fpage>288</fpage>–<lpage>291</lpage>.</citation></ref>
<ref id="bibr3-0961203311433139"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petri</surname></name><name><surname>Michelle</surname></name><name><surname>SLICC</surname></name></person-group>. <article-title>SLICC Revision of the ACR Classification Criteria for SLE</article-title>. <source>Arthritis Rheum</source> <year>2009</year>; <volume>60</volume>(<issue>Suppl</issue>): <fpage>895</fpage>–<lpage>895</lpage>. <comment>(abstract)</comment>.</citation></ref>
<ref id="bibr4-0961203311433139"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maddison</surname><given-names>PJ</given-names></name></person-group>. <article-title>ANA-negative SLE</article-title>. <source>Clin Rheum Dis</source> <year>1982</year>; <volume>8</volume>: <fpage>105</fpage>–<lpage>119</lpage>.</citation></ref>
<ref id="bibr5-0961203311433139"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paz</surname><given-names>E</given-names></name><name><surname>Adawi</surname><given-names>M</given-names></name><name><surname>Lavi</surname><given-names>I</given-names></name><name><surname>Mussel</surname><given-names>Y</given-names></name><name><surname>Mader</surname><given-names>R</given-names></name></person-group>. <article-title>Antinuclear antibodies measured by enzyme immunoassay in patients with systemic lupus erythematosus: relation to disease activity</article-title>. <source>Rheumatol Int</source> <year>2007</year>; <volume>27</volume>: <fpage>941</fpage>–<lpage>945</lpage>.</citation></ref>
<ref id="bibr6-0961203311433139"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>BILAG, SLEDAI, SIS, ECLAM, WAM, SLAM … thank you MAM</article-title>. <source>Lupus</source> <year>2007</year>; <volume>16</volume>: <fpage>849</fpage>–<lpage>851</lpage>.</citation></ref>
<ref id="bibr7-0961203311433139"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yee</surname><given-names>CS</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name><name><surname>Prabu</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000</article-title>. <source>Ann Rheum Dis</source> <year>2008</year>; <volume>67</volume>: <fpage>873</fpage>–<lpage>876</lpage>.</citation></ref>
<ref id="bibr8-0961203311433139"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ibanez</surname><given-names>D</given-names></name><name><surname>Gladman</surname><given-names>D</given-names></name><name><surname>Urowitz</surname><given-names>M</given-names></name></person-group>. <article-title>Summarizing disease features over time: II. Variability measures of SLEDAI-2K</article-title>. <source>J Rheumatol</source> <year>2007</year>; <volume>34</volume>: <fpage>336</fpage>–<lpage>340</lpage>.</citation></ref>
<ref id="bibr9-0961203311433139"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>MH</given-names></name></person-group>. <article-title>Can the adjusted mean SLEDAI-2K predict organ damage and coronary artery disease?</article-title> <source>Nat Clin Pract Rheumatol</source> <year>2006</year>; <volume>2</volume>: <fpage>10</fpage>–<lpage>11</lpage>.</citation></ref>
<ref id="bibr10-0961203311433139"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uribe</surname><given-names>AG</given-names></name><name><surname>Vila</surname><given-names>LM</given-names></name><name><surname>McGwin</surname><given-names>G</given-names><suffix>Jr</suffix></name><name><surname>Sanchez</surname><given-names>ML</given-names></name><name><surname>Reveille</surname><given-names>JD</given-names></name><name><surname>Alarcon</surname><given-names>GS</given-names></name></person-group>. <article-title>The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus</article-title>. <source>JRheumatol</source> <year>2004</year>; <volume>31</volume>: <fpage>1934</fpage>–<lpage>1940</lpage>.</citation></ref>
<ref id="bibr11-0961203311433139"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawker</surname><given-names>G</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Bombardier</surname><given-names>C</given-names></name><name><surname>Goldsmith</surname><given-names>C</given-names></name><name><surname>Caron</surname><given-names>D</given-names></name><name><surname>Gladman</surname><given-names>D</given-names></name></person-group>. <article-title>A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>1993</year>; <volume>20</volume>: <fpage>657</fpage>–<lpage>660</lpage>.</citation></ref>
<ref id="bibr12-0961203311433139"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meryhew</surname><given-names>NL</given-names></name><name><surname>Messner</surname><given-names>RP</given-names></name><name><surname>Tan</surname><given-names>EM</given-names></name></person-group>. <article-title>Urinary excretion of antinuclear antibodies</article-title>. <source>J Rheumatol</source> <year>1983</year>; <volume>10</volume>: <fpage>913</fpage>–<lpage>919</lpage>.</citation></ref>
<ref id="bibr13-0961203311433139"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>RC</given-names><suffix>Jr.</suffix></name><name><surname>Malone</surname><given-names>CC</given-names></name><name><surname>Miller</surname><given-names>RT</given-names></name><name><surname>Silvestris</surname><given-names>F</given-names></name></person-group>. <article-title>Urinary loss of immunoglobulin G anti-F(ab)2 and anti-DNA antibody in systemic lupus erythematosus nephritis</article-title>. <source>J Lab Clin Med</source> <year>1998</year>; <volume>132</volume>: <fpage>210</fpage>–<lpage>222</lpage>.</citation></ref>
<ref id="bibr14-0961203311433139"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sciascia</surname><given-names>SA</given-names></name><name><surname>Dickensheets</surname><given-names>H</given-names></name><name><surname>Picking</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Autoantibodies and autoantigens in the urine of SLE patients</article-title>. <source>Autoimmunity</source> <year>2004</year>; <volume>37</volume>: <fpage>503</fpage>–<lpage>514</lpage>.</citation></ref>
<ref id="bibr15-0961203311433139"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barnett</surname><given-names>EV</given-names></name><name><surname>North</surname><given-names>AF</given-names><suffix>Jr</suffix></name><name><surname>Condemi</surname><given-names>JJ</given-names></name><name><surname>Jacox</surname><given-names>RF</given-names></name><name><surname>Vaughan</surname><given-names>JH</given-names></name></person-group>. <article-title>Antinuclear Factors in Systemic Lupus Erythematosus and Rheumatoid Arthritis</article-title>. <source>Ann Intern Med</source> <year>1965</year>; <volume>63</volume>: <fpage>100</fpage>–<lpage>108</lpage>.</citation></ref>
<ref id="bibr16-0961203311433139"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hotchkiss</surname><given-names>RS</given-names></name><name><surname>Tinsley</surname><given-names>KW</given-names></name><name><surname>Swanson</surname><given-names>PE</given-names></name><etal/></person-group>. <article-title>Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans</article-title>. <source>J Immunol</source> <year>2001</year>; <volume>166</volume>: <fpage>6952</fpage>–<lpage>6963</lpage>.</citation></ref>
<ref id="bibr17-0961203311433139"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>LX</given-names></name><name><surname>Tan</surname><given-names>JJ</given-names></name><name><surname>Li</surname><given-names>YN</given-names></name><etal/></person-group>. <article-title>Immune and inflammation confusion in severe sepsis and effects of bi-immunomodulation therapy: a prospective, randomized, controlled clinical trial</article-title>. <source>Zhonghua Yi Xue Za Zhi</source> <year>2009</year>; <volume>89</volume>: <fpage>1028</fpage>–<lpage>1033</lpage>.</citation></ref>
<ref id="bibr18-0961203311433139"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>S</given-names></name></person-group>. <article-title>Monocyte HLA-DR expression as predictors of clinical outcome for patients with sepsis</article-title>. <source>Nippon Rinsho</source> <year>2004</year>; <volume>62</volume>: <fpage>2281</fpage>–<lpage>2284</lpage>.</citation></ref>
<ref id="bibr19-0961203311433139"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reichlin</surname><given-names>M</given-names></name></person-group>. <article-title>ANA negative systemic lupus erythematosus sera revisited serologically</article-title>. <source>Lupus</source> <year>2000</year>; <volume>9</volume>: <fpage>116</fpage>–<lpage>119</lpage>.</citation></ref>
<ref id="bibr20-0961203311433139"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>EL</given-names></name><name><surname>Provost</surname><given-names>TT</given-names></name></person-group>. <article-title>Ro (SSA) and La (SSB) antibodies</article-title>. <source>Springer Semin Immunopathol</source> <year>1981</year>; <volume>4</volume>: <fpage>253</fpage>–<lpage>273</lpage>.</citation></ref>
<ref id="bibr21-0961203311433139"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tozzoli</surname><given-names>R</given-names></name><name><surname>Bizzaro</surname><given-names>N</given-names></name><name><surname>Tonutti</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases</article-title>. <source>Am J Clin Pathol</source> <year>2002</year>; <volume>117</volume>: <fpage>316</fpage>–<lpage>324</lpage>.</citation></ref>
<ref id="bibr22-0961203311433139"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kavanaugh</surname><given-names>A</given-names></name><name><surname>Tomar</surname><given-names>R</given-names></name><name><surname>Reveille</surname><given-names>J</given-names></name><name><surname>Solomon</surname><given-names>DH</given-names></name><name><surname>Homburger</surname><given-names>HA</given-names></name></person-group>. <article-title>Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists</article-title>. <source>Arch Pathol Lab Med</source> <year>2000</year>; <volume>124</volume>: <fpage>71</fpage>–<lpage>81</lpage>.</citation></ref>
<ref id="bibr23-0961203311433139"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>DJ</given-names></name><name><surname>Linker-Israeli</surname><given-names>M</given-names></name></person-group>. <article-title>It's not the same old lupus or Sjogren's any more: one hundred new insights, approaches, and options since 1990</article-title>. <source>Curr Opin Rheumatol</source> <year>1999</year>; <volume>11</volume>: <fpage>321</fpage>–<lpage>329</lpage>.</citation></ref>
<ref id="bibr24-0961203311433139"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manz</surname><given-names>RA</given-names></name><name><surname>Thiel</surname><given-names>A</given-names></name><name><surname>Radbruch</surname><given-names>A</given-names></name></person-group>. <article-title>Lifetime of plasma cells in the bone marrow</article-title>. <source>Nature</source> <year>1997</year>; <volume>388</volume>: <fpage>133</fpage>–<lpage>134</lpage>.</citation></ref>
<ref id="bibr25-0961203311433139"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slifka</surname><given-names>MK</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name></person-group>. <article-title>Long-lived plasma cells: a mechanism for maintaining persistent antibody production</article-title>. <source>Curr Opin Immunol</source> <year>1998</year>; <volume>10</volume>: <fpage>252</fpage>–<lpage>258</lpage>.</citation></ref>
<ref id="bibr26-0961203311433139"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manz</surname><given-names>RA</given-names></name><name><surname>Radbruch</surname><given-names>A</given-names></name></person-group>. <article-title>Plasma cells for a lifetime?</article-title> <source>Eur J Immunol</source> <year>2002</year>; <volume>32</volume>: <fpage>923</fpage>–<lpage>927</lpage>.</citation></ref>
<ref id="bibr27-0961203311433139"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cambridge</surname><given-names>G</given-names></name><name><surname>Leandro</surname><given-names>MJ</given-names></name><name><surname>Edwards</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source> <year>2003</year>; <volume>48</volume>: <fpage>2146</fpage>–<lpage>2154</lpage>.</citation></ref>
<ref id="bibr28-0961203311433139"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benner</surname><given-names>R</given-names></name><name><surname>Meima</surname><given-names>F</given-names></name><name><surname>van der Meulen</surname><given-names>GM</given-names></name><name><surname>van Muiswinkel</surname><given-names>WB</given-names></name></person-group>. <article-title>Antibody formation in mouse bone marrow. I. Evidence for the development of plaque-forming cells in situ</article-title>. <source>Immunology</source> <year>1974</year>; <volume>26</volume>: <fpage>247</fpage>–<lpage>255</lpage>.</citation></ref>
<ref id="bibr29-0961203311433139"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benner</surname><given-names>R</given-names></name><name><surname>van Oudenaren</surname><given-names>A</given-names></name><name><surname>de Ruiter</surname><given-names>H</given-names></name></person-group>. <article-title>Antibody formation in mouse bone marrow. VII. Evidence against the migration of plaque-forming cells as the underlying cause for bone marrow plaque-forming cell activity: a study with parabiotic mice</article-title>. <source>Cell Immunol</source> <year>1977</year>; <volume>29</volume>: <fpage>28</fpage>–<lpage>36</lpage>.</citation></ref>
<ref id="bibr30-0961203311433139"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benner</surname><given-names>R</given-names></name><name><surname>Hijmans</surname><given-names>W</given-names></name><name><surname>Haaijman</surname><given-names>JJ</given-names></name></person-group>. <article-title>The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation</article-title>. <source>Clin Exp Immunol</source> <year>1981</year>; <volume>46</volume>: <fpage>1</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr31-0961203311433139"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slifka</surname><given-names>MK</given-names></name><name><surname>Matloubian</surname><given-names>M</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name></person-group>. <article-title>Bone marrow is a major site of long-term antibody production after acute viral infection</article-title>. <source>JVirol</source> <year>1995</year>; <volume>69</volume>: <fpage>1895</fpage>–<lpage>1902</lpage>.</citation></ref>
<ref id="bibr32-0961203311433139"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arce</surname><given-names>S</given-names></name><name><surname>Cassese</surname><given-names>G</given-names></name><name><surname>Hauser</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The role of long-lived plasma cells in autoimmunity</article-title>. <source>Immunobiology</source> <year>2002</year>; <volume>206</volume>: <fpage>558</fpage>–<lpage>562</lpage>.</citation></ref>
<ref id="bibr33-0961203311433139"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gorman</surname><given-names>C</given-names></name><name><surname>Leandro</surname><given-names>M</given-names></name><name><surname>Isenberg</surname><given-names>D</given-names></name></person-group>. <article-title>B cell depletion in autoimmune disease</article-title>. <source>Arthritis Res Ther</source> <year>2003</year>; <volume>5</volume>(<issue>Suppl. 4</issue>): <fpage>S17</fpage>–<lpage>S21</lpage>.</citation></ref>
<ref id="bibr34-0961203311433139"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Ho</surname><given-names>CT</given-names></name><name><surname>Lau</surname><given-names>CS</given-names></name><name><surname>Wong</surname><given-names>RW</given-names></name></person-group>. <article-title>A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population</article-title>. <source>Rheumatology (Oxford)</source> <year>2000</year>; <volume>39</volume>: <fpage>399</fpage>–<lpage>406</lpage>.</citation></ref>
<ref id="bibr35-0961203311433139"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iriya</surname><given-names>SM</given-names></name><name><surname>Capelozzi</surname><given-names>VL</given-names></name><name><surname>Calich</surname><given-names>I</given-names></name><name><surname>Martins</surname><given-names>MA</given-names></name><name><surname>Lichtenstein</surname><given-names>A</given-names></name></person-group>. <article-title>Causes of death in patients with systemic lupus erythematosus in Sao Paulo, Brazil: a study of 113 autopsies</article-title>. <source>Arch Intern Med</source> <year>2001</year>; <volume>161</volume>: <fpage>1557</fpage>–<lpage>1557</lpage>.</citation></ref>
<ref id="bibr36-0961203311433139"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus</article-title>. <source>Medicine (Baltimore)</source> <year>1999</year>; <volume>78</volume>: <fpage>167</fpage>–<lpage>175</lpage>.</citation></ref>
</ref-list>
</back>
</article>